| __timestamp | Corcept Therapeutics Incorporated | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 882000 | 94103000 |
| Thursday, January 1, 2015 | 1361000 | 146194000 |
| Friday, January 1, 2016 | 2058000 | 130000 |
| Sunday, January 1, 2017 | 3554000 | 7353000 |
| Monday, January 1, 2018 | 5215000 | 34193000 |
| Tuesday, January 1, 2019 | 5504000 | 56586000 |
| Wednesday, January 1, 2020 | 5582000 | 63382000 |
| Friday, January 1, 2021 | 5281000 | 97049000 |
| Saturday, January 1, 2022 | 5385000 | 139989000 |
| Sunday, January 1, 2023 | 6481000 | 150343000 |
Infusing magic into the data realm
In the ever-evolving landscape of biotechnology, understanding cost structures is pivotal. This analysis delves into the cost of revenue trends for Sarepta Therapeutics, Inc. and Corcept Therapeutics Incorporated from 2014 to 2023. Over this decade, Sarepta's cost of revenue surged by approximately 60%, peaking at 150 million in 2023. This reflects its aggressive expansion and investment in cutting-edge therapies. In contrast, Corcept's costs grew steadily, with a 635% increase, reaching 6.5 million in 2023. This growth underscores its strategic focus on niche markets. Notably, 2016 marked a unique year for Sarepta with a significant dip, highlighting potential strategic pivots or market challenges. These insights offer a window into the financial strategies of these biotech leaders, emphasizing the importance of cost management in sustaining innovation and growth.
Cost of Revenue Trends: Novo Nordisk A/S vs Sarepta Therapeutics, Inc.
Pfizer Inc. vs Sarepta Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Gilead Sciences, Inc. and Sarepta Therapeutics, Inc.
Cost Insights: Breaking Down Takeda Pharmaceutical Company Limited and Sarepta Therapeutics, Inc.'s Expenses
BeiGene, Ltd. vs Sarepta Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for United Therapeutics Corporation and Corcept Therapeutics Incorporated
Analyzing Cost of Revenue: Sarepta Therapeutics, Inc. and Grifols, S.A.
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and Perrigo Company plc's Expenses
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and Galapagos NV's Expenses
Cost of Revenue: Key Insights for Corcept Therapeutics Incorporated and Amneal Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Corcept Therapeutics Incorporated and Amphastar Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Corcept Therapeutics Incorporated and Viridian Therapeutics, Inc.